CYP17A1 and pachyonychia congenita: At this juncture, the CYP17A1 enzymebecomes critically important, influenced by mechanisms such as epigeneticalterations, genetic mutations, gene amplification, and microRNA regulation. Given the capacity of the CYP17A1 enzyme toadapt beyond the scope of current therapeutic approaches, it becomesclear that ADT alone is insufficient in advanced PC cases., This highlights an urgent need for the development of new pharmacologicalagents and therapeutic strategies that can effectively target cancercells and inhibit the autonomous production of androgens.